Overview

• The FDA declared shortages of GLP-1 weight-loss drugs Wegovy and Zepbound officially over as of May 22, 2025, banning compounded semaglutide distribution.
• Novo Nordisk announced a temporary $199 price for a one-month supply of Wegovy through June 30 for patients transitioning from compounded versions, with the price increasing to $499 afterward.
• Cigna’s Evernorth pharmacy benefits unit secured a deal to cap patient copays for Wegovy and Zepbound at $200 per month and reduce employer costs starting July 1.
• CVS Caremark finalized a formulary agreement favoring Wegovy as its primary weight-loss drug beginning in the second half of 2025, deprioritizing Eli Lilly’s Zepbound.
• Medicare price negotiations under the Inflation Reduction Act are set to further reshape the market by 2027, potentially making Novo Nordisk’s products preferred within the program.